Redhill Biopharma Ltd.

There will be a presentation followed by question and answer session, at which time if you wish to ask a question you will need to press the star and 1 on your telephone keypad. I would like to introduce to the conference call Redhill's CEO, Drew Ben Asher, Mika Ben-Turin, Redhill's Chief Financial Officer, Rick Scruggs, Redhill's Chief Commercial Officer, Gilead Rade, Redhill's Chief Operating Officer. Guy Goldberg, Redhill's Chief Business Officer. Adi Frisch, Chief Corporate and Business Development Officer. Rob Jackson, Redhill's Senior Vice President of Sales and Marketing. And Bob Gilkin, Redhill's Senior Vice President, Market Access and Trade Relations. Before we begin, we will read from the Redhill Safe Harbor Statement. Please go ahead.

Thank you, Tracy. This conference call may contain projections or other forward-looking statements regarding future events or the future performance of Redhill, including statements with respect to the business promotion and other efforts related to Redhill's commercialization activities and the initiation, timing, progress, and results of Redhill's research, manufacturing, preclinical studies, clinical trials, marketing applications, and approvals, if any, including the clinical trial trials of octagonib and RHP107 for the treatment of COVID-19. These statements are only predictions and Redhill cannot guarantee that they will in fact occur. Redhill does not assume any obligation to update that information. Actual events, performance, timing, results, or commercialization activities may differ materially from what Redhill projects today. Additional information concerning factors that could cause actual events, performance, timing, results, or commercialization activities to materially differ from those contained in the forward-looking statements can be found in the company's annual report on Form 20-F, filed with the SEC on March 18, 2021, and in its other filings with the Securities and Exchange Commission. I will now turn the call to Red Hill CEO, Dorben Asher.

Thank you, Alexandra. Good day, everyone, and thank you for joining us today. We will be presenting detailed highlights So please remember to press on the link to follow the slides. The WHO's Director General stated recently that we are on track for the second year of this pandemic to be far more deadly than the first. Red Hill understands its calling, particularly because both our advanced clinical stage drug candidates, Opaginib and IHB107, are novel, expected to address new variants, and are oral pills with patent protection until at least 2041, as we announced yesterday. Our highly motivated team is doing everything humanly possible to get to the finish line. This is evidenced by the fast progress of these two programs. Redhill is now positioned at the very forefront of novel COVID-19 therapeutic development. In fact, to the best of our knowledge, Opaginib is currently the most advanced novel dual mode of action, both antiviral and anti-inflammatory oral drug candidate of its kind in development for COVID-19. Our global 464-patient Phase 2-3 study in severe COVID-19 has been approved in 10 countries. It is almost 100% enrolled, and we eagerly await the upcoming top-line results. Our chief operating officer, Gilad, will elaborate shortly. Commercially, a very strong end to the quarter has set up 2021 for further growth. reversing a slow start to the year across the industry. Movantic new prescriptions in the first quarter outperformed the same quarter last year, prior to its acquisition by Redhill from AstraZeneca. Talicia's consistent growth in prescription volume, repeat prescribing, and new prescribers are encouraging and will likely be the key growth drivers in the coming years. We are more confident than ever about Talicia's prospects to become the new standard of care for H. pylori for years to come as the only drug both approved in the U.S. for first-line treatment and addressing head-on the main public health concern of high and growing H. pylori resistance to macrolide antibiotics. The U.S. is now emerging from the shadows of COVID-19, with patients returning to clinics and travel resuming, positively affecting also M-Colo's prospects. Rob, our head of sales and marketing, will provide additional details in a moment. To sum up, Red Hat is set for numerous near and longer-term milestones, and both organic and non-organic growth and a strong momentum. Before turning back to Guy for our presentation, please remember to press on the link in order to see our detailed slides, to be followed by a Q&A session. Guy, please.